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Abstract
Background: Anthroposophic therapies (counselling, special medication, art, eurythmy movement, and
rhythmical massage) aim to stimulate long-term self-healing processes, which theoretically could lead to a
reduction of healthcare use. In a prospective two-year cohort study, anthroposophic therapies were
followed by a reduction of chronic disease symptoms and improvement of quality of life. The purpose of
this analysis was to describe health costs in users of anthroposophic therapies.
Methods: 717 consecutive outpatients from 134 medical practices in Germany, starting anthroposophic
therapies for chronic diseases, participated in a prospective cohort study. We analysed direct health costs
(anthroposophic therapies, physician and dentist consultations, psychotherapy, medication, physiotherapy,
ergotherapy, hospital treatment, rehabilitation) and indirect costs (sick leave compensation) in the pre-
study year and the first two study years. Costs were calculated from resource utilisation, documented by
patient self-reporting. Data were collected from January 1999 to April 2003.
Results: Total health costs in the first study year (bootstrap mean 3,297 Euro; 95% confidence interval
95%-CI 3,157 Euro to 3,923 Euro) did not differ significantly from the pre-study year (3,186 Euro; 95%-CI
3,037 Euro to 3,711 Euro), whereas in the second year, costs (2,771 Euro; 95%-CI 2,647 Euro to 3,256
Euro) were significantly reduced by 416 Euro (95%-CI 264 Euro to 960 Euro) compared to the pre-study
year. In each period hospitalisation and sick-leave together amounted to more than half of the total health
costs. Anthroposophic therapies and medication amounted to 3%, 15%, and 8% of total health costs in the
pre-study year, first year, and second study year, respectively. The cost reduction in the second year was
largely accounted for by a decrease of inpatient hospitalisation, leading to a hospital cost reduction of 519
Euro (95%-CI 377 Euro to 904 Euro) compared to the pre-study year.
Conclusion: In patients starting anthroposophic therapies for chronic disease, total health costs did not
increase in the first year, and were reduced in the second year. This reduction was largely explained by a
decrease of inpatient hospitalisation. Within the limits of a pre-post design, study findings suggest that
anthroposophic therapies are not associated with a relevant increase in total health costs.
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Background
Complementary therapies are popular and extensively
used. In Germany and Switzerland some complementary
therapies are reimbursed within health care budgets. In
these countries there has been a debate as to whether
reimbursement of complementary therapies may lead to
increased overall health expenditures [1].
Anthroposophic medicine (AM) was founded in the
1920s by Rudolf Steiner and Ita Wegman [2]. AM thera-
pies are provided by physicians (counselling, AM medica-
tion) and non-medical therapists (AM art, eurythmy
movement, and massage therapy) in inpatient and outpa-
tient settings. AM aims to stimulate long-term self-healing
processes in patients [3], which theoretically could lead to
a reduction of healthcare use. Observational data suggest
AM can be associated with cost savings [4], but no studies
of total health costs have been undertaken.
The Anthroposophic Medicine Outcomes Study (AMOS)
[5] provided an opportunity to investigate total health
costs in AM users. AMOS is a prospective cohort study of
outpatients starting AM therapies for chronic disease. The
study was initiated by a health insurance company in con-
junction with a health benefit project including reim-
bursement of AM therapies [5]. AM therapies were
implemented during the first 3–6 months after study
enrolment and were followed by a substantial reduction
of disease severity and an improvement of quality of life
[5]. In a first cost analysis, the pre-study year was com-
pared to the first study year [5]. Here we present a cost
analysis with a larger patient sample, including costs in
the second study year.
Methods
Objective and design
The objective was to study health costs in AM therapy
users from the societal perspective. For this purpose, we
analysed health service use in a prospective cohort study
of patients starting AM therapies for chronic disease, and
calculated health costs. We calculated total (direct and
indirect) costs in the first and second years after study
entry and compared them to costs in the pre-study year.
For each year we determined the relative size of AM ther-
apy costs vs. total health costs. Exploratory subgroup anal-
yses were performed for different age and therapy groups.
Setting, participants, and therapy
Participating physicians were certified by the Physicians'
Association for Anthroposophical Medicine in Germany
and had an office-based practice or worked in outpatient
clinics in Germany. The physicians recruited consecutive
patients starting AM therapy. Patients enrolled in the
period 1 Jan 1999 to 31 March 2001 were included in the
present analysis (18- and 24-month follow-ups were not
performed for patients enrolled before 1 Jan 1999; n = 87)
if they fulfilled eligibility criteria:
Inclusion criteria: (a) Outpatients aged 1–75 years, (b)
referral to AM therapy (art, eurythmy or rhythmical mas-
sage), or initial AM-related consultation ≥ 30 min for any
indication (main diagnosis), (c) at least three out of five
follow-up questionnaires returned within the first two
study years.
Exclusion criteria: previous AM therapy (art/eurythmy/
rhythmical massage/AM-related consultation ≥ 30 min)
for main diagnosis, respectively.
Therapy: Patients were treated according to the physician's
discretion.
Outcome measures
Health costs, regardless of diagnosis, in the pre-study year
and in the first and second study years: direct health costs
(AM therapies, physician and dentist consultations, psy-
chotherapy, medication, physiotherapy, ergotherapy,
inpatient hospital and rehabilitation treatment), indirect
costs (sick leave compensation).
Data collection
All data were documented with questionnaires sent in
sealed envelopes to the study office. Physicians docu-
mented eligibility criteria and baseline health status; all
other items were documented by patients. Patient
responses were not made available to physicians. Physi-
cians were compensated 40 Euro per included and fully
documented patient, while patients received no compen-
sation.
Data were entered twice by two different persons into
Microsoft® Access 97. The two datasets were compared and
discrepancies resolved by checking with the original data.
Quality assurance, adherence to regulations
The study was approved by the Ethics Committee of the
Faculty of Medicine Charité, Humboldt University Berlin,
and was conducted according to the Helsinki Declaration
and ICH-GCP guidelines. Written informed consent was
obtained from all patients before enrolment.
Data analysis
Data analysis (SPSS® 13.0.1, StatXact® 5.0.3, S-PLUS® 7.0)
was performed on all patients fulfilling eligibility criteria.
For total and hospital costs, bootstrap means with bias-
corrected and accelerated (BCa) bootstrap 95% confi-
dence intervals (95%-CI) were calculated, using 2000 rep-
lications per analysis [6]. For other continuous data
Wilcoxon Signed-Rank test was used for paired samples,
Mann-Whitney U-test for independent samples; medianBMC Health Services Research 2006, 6:65 http://www.biomedcentral.com/1472-6963/6/65
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differences with 95%-CI were estimated according to
Hodges and Lehmann [7]. For binominal data McNemar
test and Fisher's exact test were used. All tests were two-
tailed. Significance criteria were p < 0.05 and 95%-CI not
including 0.
Resource utilisation (therapies and health services) were
analysed replacing missing data for each item and follow-
up period by the group mean value. Costs were analysed
from the perspective of the payer (employer: sick-leave
costs for first six weeks; statutory health insurance: direct
costs and sick-leave costs beyond first six weeks). Patient
co-payment was not subtracted from direct costs.
Unit costs (Table 1) were calculated from average costs per
item in Germany, year 2000 value (physicians' and den-
tists' fees, medication, hospital, rehabilitation, sick-leave
costs [8,9]) or from reimbursement fees regulated in
health care benefit catalogues (AM therapies, paraclinical
investigations, psychotherapy, physiotherapy, ergother-
apy [10-13]).
Hospital costs were calculated from average costs in each
German federal state [14]. Physicians' fees were calculated
from average fees of general practitioners + 12 specialist
categories in the Accounting Data Record Panel of the
Central Research Institute of Ambulatory Health Care in
Germany [15]. Costs for paraclinical investigations (x-
rays, computer tomography scans, nuclear magnetic reso-
nance imaging and scintigrams) were calculated sepa-
rately [11]. Costs of AM medication (any medication
produced by the pharmaceutical companies Abnoba
Arzneimittel GmbH, Helixor Heilmittel GmbH & Co,
WALA Heilmittel GmbH, and Weleda AG) were calculated
from average costs in 51 different price groups. Costs of
other medications were calculated from national average
costs in 86 Anatomical Therapeutic Chemical subgroups
[16]. Sick-leave costs were calculated from national aver-
age gender-specific earnings for civil servants, salaried
employees, and wage earners (100% compensation for
sick-leave days 1–42, 70% compensation thereafter) [9].
Costs were not discounted.
Results
Participating physicians
153 physicians screened patients. 134 physicians had
evaluable patients; these physicians did not differ signifi-
cantly from all AM-certified physicians in Germany (n =
362) regarding gender (56.7% vs. 62.2% males), age
(mean 46.3 ± 7.2 vs. 47.5 ± 7.9 years), number of years in
practice (18.5 ± 7.5 vs. 18.9 ± 7.3 years), or the proportion
of primary care physicians (86.6% vs. 85.0%).
Patient recruitment and follow-up
From 1 Jan 1999 to 31 March 2001, a total of 999 patients
were screened for inclusion. 717 patients fulfilled all eligi-
bility criteria and were included in the analysis (Figure 1).
Included and not included patients did not differ signifi-
cantly regarding age, gender, diagnosis, disease duration,
or baseline symptom severity. The last patient follow-up
ensued on 30 April 2003. 74.3% (533/717) of patients
were enrolled by general practitioners, 10.2% by
internists, 5.7% by paediatricians, and 9.8% by other spe-
cialist physicians. Physicians' setting was primary care
practice (87.2% of patients, n = 625/717), referral practice
(7.9%), and outpatient clinic (4.9%). Each physician
enrolled median 3.0 patients (interquartile range IQR
2.0–7.0 patients).
Table 1: Cost calculation
Health service 
category
Measurement 
unit
Categories/subgroups analysed separately Unit cost 
(range) in Euro
Cost type* Source
AM therapies Therapy session Eurythmy, art, rhythmical massage 19.9 – 32.2 Fee [10]
AM medication Daily dose 51 price groups 0.1 – 5.2 Price Manufacturer's 
price lists
Physician visit Visit 12 specialist categories 12.3 – 28.6 Cost [15]
Dentist visit Visit (excluding dental prosthesis) 62.4 Cost [8]
Psychotherapy Therapy session 56.1 Fee [11]
Paraclinical investigation Investigation X-rays, computer tomography scans, nuclear 
magnetic resonance imaging, scintigrams
17.4 – 200.3 Fee [11]
Non-AM medication Daily dose 86 ATC groups 0.1 – 37.1 Price [16]
Physiotherapy Therapy session Remedial gymnastics, exercise therapy, massage, 
fango packs, aerothermotherapy, other
5.7 – 13.7 Fee [12]
Ergotherapy Therapy session 24.9 Fee [13]
Inpatient hospitalisation Day 16 Federal states 271.0 – 411.0 Cost [14]
Inpatient rehabilitation Day 58.0 Cost IKK Hamburg
Sick leave Day Days 1–42 vs. Days >42/self- employed, civil 
servants, salaried employees, wage earners, 
unemployed/males vs. females
41.5 – 113.1 Cost [9]
Fees: Fee regulated in health benefit catalogues. Cost: Average annual costs in Germany. Price: Average pharmacy retail price in each medication 
subgroup.BMC Health Services Research 2006, 6:65 http://www.biomedcentral.com/1472-6963/6/65
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Baseline characteristics
Most frequent main diagnoses, classified by ICD-10
(International Classification of Diseases, Tenth Edition),
were F00-F99 Mental Disorders (31.8%, 228/717
patients), M00-M99 Musculoskeletal Diseases (19.0%),
J00-J99 Respiratory Diseases (8.8%), and G00-G99 Nerv-
ous System Diseases (7.0%). Median disease duration was
3.0 (IQR 0.9–8.0) years. 78.8% (565/717) of patients had
at least one comorbid disease, median 1.0 (IQR 1.0–3.0)
comorbid diseases per patient. Most common comorbid
diseases, classified by ICD-10, were M00-M99 Muscu-
loskeletal Diseases (15.3%, 184/1206 diagnoses), F00-
F99 Mental Disorders (14.3%), I00-I99 Circulatory Sys-
tem Diseases (8.3%), E00-E90 Endocrine, Nutritional and
Metabolic Diseases, and J00-J99 Respiratory Diseases
(8.0%). Patients were recruited from 15 of 16 German
federal states. Median age was 39.0 (IQR 22.0–48.0)
years. Compared to the German population, patients had
higher educational and occupational levels, had less daily
alcohol consumers and regular smokers, and were less
overweight; patients' socio-demographic status was simi-
lar to the population regarding low-income, living alone,
severe disability status, and sport; and less favourable for
work disability pension and sick-leave (Table 2).
Resource utilisation
Compared to the pre-study year, the use of AM therapies
was increased during both the first and the second study
year, medication use and psychotherapy increased in the
first year but not in the second year, whereas the number
of hospital and rehabilitation days decreased progres-
sively and were significantly decreased in the second year
(Table 3).
Costs
Total health costs averaged 3,186 Euro (bootstrap mean
3,186 Euro; 95%-CI 3,037 Euro to 3,711 Euro) per patient
in the pre-study year and 3,302 Euro (bootstrap mean
3,297 Euro; 95%-CI 3,157 Euro to 3,923 Euro) in the first
study year, an increase of 123 Euro (95%-CI -391 Euro to
+320 Euro) from the pre-study year. In the second study
year, total costs were 2,768 Euro (bootstrap mean 2,771
Euro; 95%-CI 2,647 Euro to 3,256 Euro) a decrease of 416
Euro (95%-CI 264 Euro to 960 Euro) from the pre-study
year (Table 4). Cost distribution was highly skewed in all
periods; in the first study year, 5% of patients caused 38%
of all costs. In each year hospital costs and sick-leave com-
pensation together amounted to more than half of the
costs. Costs of AM therapies and medication amounted to
3%, 15%, and 8% of total health costs in the pre-study
year, first year, and second study year, respectively.
In the first study year the largest cost differences from the
pre-study year were observed for AM therapies (nominal
increase of 347 Euro per patient) and inpatient hospital
costs (nominal decrease of 310 Euro, estimated decrease
of 314 Euro, 95%-CI 130 Euro to 753 Euro); in the second
year the largest differences from the pre-study year were
again for AM therapies (nominal increase of 108 Euro)
and hospital costs (nominal decrease of 513 Euro, esti-
mated decrease of 519 Euro; 95%-CI 377 Euro to 904
Euro). Other costs differed little (differences < 50 Euro per
patient and year).
Total health costs were analysed in age and therapy groups
(Table 5). Average costs in the first study year varied by a
factor of 3.3 between age groups (1–19 years: 1416 Euro,
40–59 years: 4646 Euro) and by a factor of 1.5 between
AM therapy groups (medical: 2614 Euro, art therapy:
3706 Euro).
Discussion
We analysed direct and indirect health costs in German
outpatients starting AM therapies for chronic disease
Patient recruitment and follow-up Figure 1
Patient recruitment and follow-up.
Not included: n = 282 
• Patients’ questionnaire missing: n = 57 
• Physician’s questionnaire missing: n = 26 
• Patients’ and physician’s questionnaire dated > 30 days apart: n = 58
• No informed consent: n = 9 
• Less than three follow-up questionnaires available: n = 94 
• Other reasons: n = 38 
Included in analysis:
n = 717 
Screened patients
1.1.99-31.03.01: 
n = 999BMC Health Services Research 2006, 6:65 http://www.biomedcentral.com/1472-6963/6/65
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under routine conditions. Compared to the pre-study
year, costs did not differ significantly in the first year after
enrolment, whereas in the second year costs were signifi-
cantly reduced by 13% (416 Euro per patient).
Strengths of this study include a large patient sample, a
long follow-up period, high follow-up rates, and the par-
ticipation of 37% of all AM-certified physicians in Ger-
many. Participants resembled all eligible physicians with
respect to socio-demographic characteristics, and
included patients resembled not included, screened
patients regarding baseline characteristics. These features
suggest that the study to a high degree mirrors contempo-
rary AM use in outpatient settings. Moreover, since
patients with all diagnoses were included, our study offers
a comprehensive picture of AM practice. Therefore, in the
present early phase of economic AM evaluation, the inclu-
sion of all diagnoses is an advantage. On the other hand,
we did not attempt to separate disease-specific costs from
overall health costs. Our analysis is comprehensive,
including cost domains (physician and dentist services,
psychotherapy, physiotherapy, ergotherapy, medication,
inpatient treatment, sick-leave compensation) amounting
to 87% of healthcare expenditures of the German Statu-
tory Health System [8] (13% not analysed: dentures, med-
ical appliances, nursing, patient transport, and health
prevention programs).
A limitation of the study is the absence of a comparison
group. We do not know if in similar patients in similar set-
tings receiving conventional or no treatment, costs would
have increased, been stable, or been reduced.
Another limitation is that cost analysis was not based on
direct cost measurement but on patient self-reporting of
resource utilisation, which can be affected by recall bias.
In this pre-post analysis, however, any systematic recall
bias would probably have been conservative, making
Table 2: Socio-demographic data
Items Study patients German primary care 
patients
N% % S o u r c e
Female gender 520/717 73% 53% [23]
Age groups 0–19 years 176/717 25% 14% [23]
20–39 years 201/717 28% 27%
40–59 years 269/717 38% 27%
60–75 years 71/717 10% 21%
Adult study 
patients
German population
"Fachhochschule" or university entrance qualification 302/545 55% 19% [9]
University degree 132/544 24% 6% [9]
Occupational status in the last 12 months Gainfully employed patients [9]
-Self-employed 47/281 17% 10%
-Civil servants ("Beamter") 19/281 7% 7%
-Salaried employee ("Angestellte") 189/281 67% 49%
-Wage earners ("Arbeiter") 11/281 4% 34%
-Other 15/281 5% 1%
Unemployed in the last 12 months Economically active 
patients
10/291 3% 10% [9]
Living alone 106/540 20% 21% [9]
Net family income < 900 Euro per month 62/451 14% 16% [9]
Alcohol use daily (patients) vs. almost daily (Germany) Male 3/102 3% 28% [24]
Female 11/443 2% 11%
Regular smoking Male 10/102 10% 37% [25]
Female 46/442 10% 28%
Sports activity ≥ 1 hour weekly Age 25–69 236/505 47% 39% [26]
Body mass index ≥ 25 (overweight) Male 25/101 25% 56% [9]
Female 111/437 25% 39%
Permanent work disability pension 43/545 8% 3% [27]
Severe disability status 54/545 10% 12% [28]
Sick leave days in the last 12 months (mean ± SD) Economically active 
patients
27.9 ± 58.0 days 17.0 days [29]BMC Health Services Research 2006, 6:65 http://www.biomedcentral.com/1472-6963/6/65
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results appear less favourable. The reason is: While at
study entry patients were asked about therapies and
health services during the preceding 12 months, these
items were thereafter asked every six months (medicine
use also after three months). Since patients' recall of
resource utilisation declines over time with a net tendency
towards under-reporting [17], under-reporting is more
likely for the 12-month pre-study period than for the
shorter periods after study entry.
Dropout is unlikely to have biased the analysis of resource
utilisation: For this analysis, 88% of patients were evalua-
ble. Moreover, there is no a priori reason to assume that
therapies and health services are used differently by drop-
outs and respondents.
Since patients were treated by AM physicians who could
possibly have an interest in AM therapies having favoura-
ble outcomes, study data were largely collected by patients
and not physicians. For this analysis, any bias affecting
physician's documentation would not affect outcomes
(resource utilisation), since these outcomes were docu-
mented by patients. Also, physicians' documentation of
baseline health status (main and comorbid diagnoses)
did not affect patient recruitment, since patients were
enrolled regardless of diagnoses.
Major determinants of cost changes were an increased use
of AM therapies (corresponding to a cost increase from
the pre-study year of 377 Euro and 116 Euro per patient
in the first and second year, respectively) and a reduction
of hospitalisation (corresponding to a cost reduction of
310 Euro and 513 Euro, respectively), whereas other costs
differed by less than 50 Euro per year. The increase of AM
therapies is a consequence of the study inclusion criterion
of patients starting new AM therapies. The reduction in
Table 4: Health costs per patient and year (Euro)
Item Pre-study year 0–12 months 12–24 months
Mean ± SD Percentage 
of costs
Mean ± SD Percentage 
of costs
Mean ± SD Percentage 
of costs
AM therapies 51 ± 186 1.6% 398 ± 400 12.1% 159 ± 334 5.7%
AM medication 58 ± 145 1.8% 88 ± 164 2.7% 65 ± 166 2.3%
Total AM costs 108 ± 244 3.4% 485 ± 451 14.7% 224 ± 378 8.1%
Physician visits, paraclinical investigations 247 ± 264 7.7% 234 ± 226 7.1% 225 ± 686 8.1%
Psychotherapy 179 ± 727 5.6% 211 ± 619 6.4% 211 ± 600 7.6%
Dentist visits 155 ± 221 4.9% 155 ± 206 4.7% 163 ± 182 5.9%
Non-AM medication 219 ± 464 6.9% 259 ± 507 7.8% 229 ± 517 8.3%
Physiotherapy, ergotherapy 103 ± 232 3.2% 112 ± 286 3.4% 116 ± 271 4.2%
Inpatient hospital treatment 1224 ± 4646 38.4% 914 ± 5052 27.7% 711 ± 3741 25.7%
Inpatient rehabilitation 114 ± 468 3.6% 104 ± 424 3.1% 73 ± 321 2.6%
Total non-AM direct costs 2241 ± 5092 70.3% 1989 ± 5444 60.2% 1728 ± 4160 62.4%
Total direct costs 2349 ± 5158 73.7% 2474 ± 5605 74.9% 1952 ± 4331 70.5%
Sick leave compensation 837 ± 2702 26.3% 828 ± 3099 25.1% 816 ± 2835 29.5%
Total costs 3186 ± 6447 100.0% 3302 ± 6798 100.0% 2768 ± 5483 100.0%
Table 3: Health resource utilisation per patient and year
Item Pre-study year 0–12 months 12–24 months
Mean ± SD Mean ± SD Median difference (95%-
CI) from pre-study year
P-value Mean ± SD Median difference (95%-
CI) from pre-study year
P-value
AM therapy sessions 1.58 ± 5.84 12.66 ± 12.70 +14.49 (13.50 to 15.00) < 0.001 5.10 ± 10.72 +6.59 (5.39 to 7.50) < 0.001
AM medicines per day 0.44 ± 0.80 0.73 ± 0.88 +0.28 (0.23 to 0.34) < 0.001 0.43 ± 0.74 +0.01 (-0.03 to +0.05) 0.647
Non-AM medicines per day 0.69 ± 0.99 0.77 ± 1.03 +0.05 (0.01 to 0.09) 0.015 0.66 ± 0.96 -0.03 (-0.07 to +0.02) 0.203
Physician and dentist visits 18.30 ± 19.93 18.41 ± 16.45 +0.69 (0.00 to +0.50) 0.047 17.45 ± 36.42 -1.45 (-2.00 to -0.50) 0.003
Paraclinical investigations 1.08 ± 1.65 0.92 ± 2.03 -0.50 (-0.50 to 0.00) < 0.001 0.83 ± 1.57 -0.30 (-0.58 to -0.27) < 0.001
Psychotherapy sessions 3.19 ± 12.96 3.76 ± 11.02 +2.00 (0.43 to 4.00) 0.027 3.75 ± 10.69 +2.34 (1.67 to 2.86) < 0.001
Hospital days 4.07 ± 15.65 2.92 ± 15.76 -2.00 (-4.24 to 0.00) 0.035 2.29 ± 11.84 -1.55 (-3.00 to -0.05) 0.037
Rehabilitation days 1.97 ± 8.06 1.79 ± 7.31 -0.50 (-3.50 to +7.00) 0.598 1.26 ± 5.54 -0.62 (-0.69 to 0.56) 0.004
Physiotherapy sessions 9.09 ± 20.40 10.65 ± 26.18 +1.00 (-0.55 to +4.00) 0.232 10.93 ± 26.08 +1.91 (-0.20 to +4.00) 0.092
Sick leave days* 27.92 ± 57.96 28.43 ± 69.02 -2.07 (-6.00 to +1.50 0.209 28.44 ± 64.85 -0.50 (-4.50 to +3.00) 0.614
*economically active patients, n = 291.BMC Health Services Research 2006, 6:65 http://www.biomedcentral.com/1472-6963/6/65
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hospitalisation was paralleled by a reduction of disease
severity and improvement in quality of life [5] and may
thus be related to successful therapies or spontaneous
improvement. Another possible cause is frequent or long
hospitalisation early in the course of disease (diagnosis,
therapy initiation) followed by a normalisation of hospi-
talisation rates. Sensitivity analysis, however, suggests that
this factor could at maximum explain 37% of the hospi-
talisation reduction in the second year (primary analysis:
decrease by average 1.78 days = 100%, compared to the
pre-study year; patients with disease duration of at least
one year: decrease by 1.13 days = 63%).
Moreover, changes in health-care implementation may
affect the frequency and duration of hospital treatment.
However, during this study, the average number of hospi-
tal days per person-year in Germany decreased by only
0.21 days (1999–2003: 2.07→1.86 days) [18]. This reduc-
tion of 0.11 days per two years corresponds to only 6% of
the observed reduction of 1.78 days per two years in our
study patients. Therefore, the reduced hospitalisation in
our study cannot be explained by changes in health-care
implementation. A possible setting-related cause of
reduced hospitalisation is the policy of AM general practi-
tioners to provide more comprehensive patient care and
avoid unnecessary referrals to secondary care [3,19]. Study
implications: The reduction of hospital treatment in this
cohort following AM therapies is in accordance with other
findings: In two Dutch studies [20,21] and a British NHS
audit [22] patients of AM physicians had 10%–35% less
hospital days than local or national averages.
In Germany, patients may use specialist health services
without referral from a primary care physician, generating
additional costs. Our study is the first economic analysis
of AM therapies taking into account such direct health
costs generated outside the AM setting, as well as indirect
costs (sick-leave compensation). In the first study year,
costs of AM therapies amounted to 15% of total health
costs and were largely outweighed by the reduced hospital
costs; therefore, total costs were not significantly increased
from the pre-study-year (as found in our previous analysis
of a smaller patient sample of this study [5]), and in the
second year a cost decrease of 416 Euro per patient (boot-
strap 95%-CI indicating a decrease of at least 264 Euro)
was found.
Conclusion
In patients starting anthroposophic therapies for chronic
disease, costs did not increase in the first year, in spite of
the intensified therapy. In the second year, a reduction of
costs was observed. This reduction was largely explained
by a decrease of inpatient hospitalisation. Within the lim-
its of a pre-post design, our findings suggest that anthrop-
osophic healthcare in Germany is not associated with a
relevant increase in total health costs.
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Table 5: Total health costs per patient and year in subgroups (Euro)
Pre-study year 0–12 months 12–24 months
N Mean ± SD Mean ± SD Mean ± SD
Age groups
0–19 years 176 1372 ± 5177 1416 ± 3121 967 ± 1056
20–39 years 201 3296 ± 5889 3109 ± 4575 3272 ± 7356
40–59 years 269 4254 ± 7390 4646 ± 9607 3337 ± 5225
60–75 years 71 3323 ± 6101 3433 ± 4384 3651 ± 5884
AM therapy groups
Eurythmy 339 3079 ± 6563 3413 ± 6101 2723 ± 4786
Art therapy 136 3898 ± 7417 3706 ± 10147 2599 ± 3660
Rhythmical massage 60 2601 ± 3236 3845 ± 6346 3300 ± 4197
Medical 182 3046 ± 6244 2614 ± 4762 2804 ± 7764
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